Loading
A phase 2 trial of Lunresertib run by Canadian Cancer Trials Group, now recruiting.
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer is a phase 2 interventional study registered as NCT05601440 by Canadian Cancer Trials Group, with 484 participants planned, started 2023-06-13. Conditions recorded: Breast Cancer. Interventions recorded: RP-6306, Gemcitabine, Observation, Niraparib, Fulvestrant, RP-3500, CFI-402257, CFI-400945 and Sacituzumab govitecan.
Shares Lunresertib, Repare Therapeutics, Debiopharm and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm and the tag pipeline.
Shares CFI-402257, Breast cancer (all types) and the tag pipeline.
Shares CFI-402257, Breast cancer (all types) and the tag pipeline.
Shares CFI-400945, Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/